Two safety concerns have been highlighted regarding temporary ovarian suppression with GnRHa during chemotherapy, particularly in patients with estrogen receptor-positive breast cancer: a potential antagonism of endocrine therapy with chemotherapy and a possible negative prognostic effect of POI prevention [69]. This evidence concerns the gene ESR1 and breast cancer.